Financial Engines Advisors L.L.C. Has $1.88 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Financial Engines Advisors L.L.C. lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 102.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,209 shares of the medical research company’s stock after buying an additional 3,641 shares during the quarter. Financial Engines Advisors L.L.C.’s holdings in Amgen were worth $1,879,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $29,000. Centricity Wealth Management LLC bought a new stake in Amgen in the fourth quarter valued at about $25,000. Synergy Investment Management LLC acquired a new position in Amgen in the fourth quarter valued at about $34,000. Atala Financial Inc bought a new position in Amgen during the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen in the 4th quarter valued at about $36,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on AMGN. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Leerink Partners decreased their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Finally, Bank of America raised their price target on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.04.

Amgen Trading Down 0.4 %

Shares of Amgen stock opened at $305.71 on Thursday. The stock has a market cap of $164.23 billion, a P/E ratio of 40.49, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The business’s 50 day moving average is $299.66 and its 200-day moving average is $298.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.11%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.